Merck· @Merck · X·· 22 天前精选AI 评分62
AI 导读
默沙东宣布已在学术场合公布针对部分晚期或复发性子宫内膜癌患者的III期突破性数据。公司表示将继续推进治疗选择,以应对该疾病尚未满足的需求,并附链接供了解详情。
推荐理由
默沙东以第一方身份披露晚期或复发性子宫内膜癌III期数据,读者可据此了解该适应症在研方案的进展。
正文
Today, we presented late-breaking Phase 3 data in certain patients with advanced or recurrent #EndometrialCancer. We remain committed to advancing treatment options that can address unmet needs for those living with this disease. Learn more: https://go.merck.com/~82i
来源:Merck · x.com